Search results for "Corticosteroid"

showing 5 items of 195 documents

Pharmacogenomics: A Step forward Precision Medicine in Childhood Asthma.

2022

Personalized medicine, an approach to care in which individual characteristics are used for targeting interventions and maximizing health outcomes, is rapidly becoming a reality for many diseases. Childhood asthma is a heterogeneous disease and many children have uncontrolled symptoms. Therefore, an individualized approach is needed for improving asthma outcomes in children. The rapidly evolving fields of genomics and pharmacogenomics may provide a way to achieve asthma control and reduce future risks in children with asthma. In particular, pharmacogenomics can provide tools for identifying novel molecular mechanisms and biomarkers to guide treatment. Emergent high-throughput technologies, …

pharmacogenomicscorticosteroidpharmacogenomictreatmentGenomicsAsthmacorticosteroidschildrenleukotriene antagonists2-agonistPharmacogeneticsasthma children corticosteroids genetics leukotriene antagonists pharmacogenomics treatment β2-agonistsleukotriene antagonistGeneticsHumansgeneticPrecision MedicineChildβ2-agonistsGenetics (clinical)BiomarkersGenes
researchProduct

Mucin 1 deficiency mediates corticosteroid insensitivity in asthma

2019

BACKGROUND: The loss of corticosteroid efficacy is an important issue in severe asthma management and may lead to poor asthma control and deterioration of airflow. Recent data indicate that Mucin 1 (MUC1) membrane mucin can mediate corticosteroid efficacy in chronic rhinosinusitis, but the role of MUC1 in uncontrolled severe asthma is unknown. The objective was to analyze the previously unexplored role of MUC1 on corticosteroid efficacy in asthma. METHODS: Mucin 1 expression was evaluated by real-time PCR in human bronchial epithelial cells (HBEC) and blood neutrophils from uncontrolled severe asthma (n=27), controlled mild asthma (n=16), and healthy subjects (n=13). IL-8, MMP9, and GM-CSF …

severe asthma0301 basic medicineLipopolysaccharideNeutrophilsmedicine.drug_classcorticosteroid insensitivityImmunologyAnti-Inflammatory AgentsDrug ResistanceMUC1DexamethasoneMice03 medical and health scienceschemistry.chemical_compoundReceptors Glucocorticoid0302 clinical medicineGlucocorticoid receptorAdrenal Cortex Hormonesimmune system diseasesmedicineAnimalsHumansImmunology and AllergyCells CulturedMUC1DexamethasoneAsthmabiologybusiness.industryMucin-1MucinEpithelial Cellsmedicine.diseaseAsthmarespiratory tract diseasesOvalbumin030104 developmental biology030228 respiratory systemchemistryCase-Control StudiesImmunologybiology.proteinCorticosteroidbusinessmedicine.drugAllergy
researchProduct

Real-world experience with dupilumab in severe asthma: One-year data from an italian named patient program

2021

Raffaele Campisi,1 Claudia Crimi,1 Santi Nolasco,2 Bianca Beghè,3 Leonardo Antonicelli,4 Gabriella Guarnieri,5 Nicola Scichilone,6 Morena Porto,2 Luigi Macchia,7 Giulia Scioscia,8 Maria Pia Foschino Barbaro,8 Alberto Papi,9 Nunzio Crimi1,2 1Respiratory Medicine Unit, A.O.U. Policlinico “G. Rodolico -San Marco”, Catania, Italy; 2Department of Clinical and Experimental Medicine, Section of Respiratory Diseases, University of Catania, Catania, Italy; 3Respiratory Medicine Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 4Allergy Unit, Department of Internal Medicine, Ancona University Hospital, Ancona, Italy; 5Department of Car…

severe asthmaPulmonary and Respiratory MedicineSevere asthmareal-worldmedicine.medical_specialtyTreatment responseSevere asthmaSocio-culturaleDupilumab Named Patient Program Oral corticosteroids Real-world Severe asthmaHypereosinophiliaDupilumaboral corticosteroidsSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionNamed Patient Program dupilumab oral corticosteroids real-world severe asthma03 medical and health sciences0302 clinical medicineRandomized controlled triallawdupilumabInternal medicineOral corticosteroidsJournal of Asthma and AllergymedicineImmunology and Allergy0601 history and archaeologyOriginal Research060102 archaeologybusiness.industryRetrospective cohort study06 humanities and the artsRC581-607Named Patient ProgramEosinophilDupilumabmedicine.anatomical_structureReal-world030228 respiratory systemCohortImmunologic diseases. Allergymedicine.symptombusinessDupilumab; Named Patient Program; Oral corticosteroids; Real-world; Severe asthma
researchProduct

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer

2020

ABSTRACT Glucocorticosteroids (GCS) have an established role in oncology and are administered to cancer patients in routine clinical care and in drug development trials as co-medication. Given their strong immune-suppressive activity, GCS may interfere with immune-oncology drugs. We are developing a therapeutic cancer vaccine, which is based on a liposomal formulation of tumor-antigen encoding RNA (RNA-LPX) and induces a strong T-cell response both in mice as well as in humans. In this study, we investigated in vivo in mice and in human PBMCs the effect of the commonly used long-acting GCS Dexamethasone (Dexa) on the efficacy of this vaccine format, with a particular focus on antigen-specif…

t-cell primingPremedicationmedicine.medical_treatmentImmunologyPriming (immunology)dexamethasoneglucocorticosteroidsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineImmune systemAntigenCancer immunotherapyNeoplasmsAnimalsHumansImmunology and AllergyMedicineRC254-282Original ResearchMice Inbred BALB Ccancer immunotherapybusiness.industryrna vaccineImmunityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC581-607Mice Inbred C57BLCytokineOncology030220 oncology & carcinogenesisImmunologyt-cell vaccineFemaleCancer vaccineImmunologic diseases. AllergybusinessT-cell vaccineResearch Article030215 immunologyOncoImmunology
researchProduct

Can adjunctive corticosteroid therapy improve patient-centered outcomes following third molar surgery? A systematic review

2021

Third molar surgery is frequently associated with postoperative discomfort such as pain, edema and trismus. We aimed to evaluate the current evidence on the efficacy of adjunctive corticosteroid therapy in improving patient-centered outcomes following third molar surgery.This systematic review assessed and searched PubMed, Google scholar, Scopus, web of science, clinicaltrials.gov and Cochrane central for controlled trials, up to May 2021. The primary outcome measures were patient-centered outcomes such as quality of life following the use of adjunctive corticosteroid therapy in third molar removal. Only randomized controlled trials published in English language were included.A total of 355…

third molars corticosteroids patient-reported outcomes health related quality of lifePain PostoperativeTooth ImpactedPainDexamethasoneOtorhinolaryngologyAdrenal Cortex HormonesPatient-Centered CareOutcome Assessment Health CareTooth ExtractionQuality of LifeEdemaHumansMolar ThirdTrismusSurgeryGeneral DentistryUNESCO:CIENCIAS MÉDICASMedicina Oral Patología Oral y Cirugia Bucal
researchProduct